Egetis Therapeutics AB (EGTX) NPV
0.06 SEK
(0.91%)
- Add to watchlist
- This stock can be held in a
0.06 SEK
(0.91%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.06 SEK
(0.91%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Contact details
Important dates
General stock information
- Short code:
- EGTX
- ISIN:
- SE0003815604
- Market cap:
- 2.39 billion SEK
- Shares in issue:
- 292.57 million
- Sector:
- Biotechnology
- Exchange:
- Stockholm Stock Exchange
- Country:
- Sweden
- Currency:
- Swedish Krona
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.